Reagent Filming for Universal Point‐of‐Care Diagnostics
Source abstract
Abstract
Abstract Simplifying assays while maintaining the robustness of reagents is a challenge in diagnostics. This problem is exacerbated when translating quality diagnostic assays to developing countries that lack resources and infrastructure such as trained health workers, high‐end equipment, and cold‐chain systems. To solve this problem, in this study, a simple solution that films assay reagents to simplify the operation of diagnostic assays and preserve the stability of diagnostic reagents without using cold chains is presented. A polyvinyl‐alcohol‐based water‐soluble film is used to encapsulate premeasured and premixed reagents. The reagent film, produced through a simple and scalable cast‐drying process, provides a glassy inner matrix with abundant hydroxyl groups that can stabilize various reagents (ranging from chemicals to biological materials) by restricting molecular mobility and generating hydrogen bonds. The reagent film is applied to an enzymatic glucose assay, a high‐sensitivity immunoassay for cardiac troponin, and a molecular assay for viral RNA detection, to test its practicability and universal applicability. The film‐based assays result in excellent analytical/diagnostic performance and stable long‐term reagent storage at elevated temperatures (at 25 or 37 °C, for six months), demonstrating clinical readiness. This technology advances the development and distribution of affordable high‐quality diagnostics to resource‐limited regions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Biosensors and Analytical Detection · SARS-CoV-2 detection and testing · Cell Image Analysis Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry School of Physics and Chemistry Gwangju Institute of Science and Technology 123 Cheomdangwagi‐ro, Buk‐gu Gwangju 61005 Republic of Korea
Funding
Ministry of Science, ICT and Future Planning · Ministry of Health and Welfare · National Research Foundation of Korea
References (63)
Show source-provided references
1. 10.1371/journal.pmed.100130610.1371/journal.pmed.1001306 ↗
2. 10.1056/NEJMsb121419710.1056/NEJMsb1214197 ↗
3. 10.1038/s41564-018-0295-310.1038/s41564-018-0295-3 ↗
4. 10.1016/S2213-2600(20)30454-910.1016/S2213-2600(20)30454-9 ↗
5. a)World Health Organization World Malaria Report 2020: 20 Years of Global Progress and Challenges https://www.who.int/publications/i/item/9789240015791(accessed: April2020);
6. b)World Health Organization Consolidated Guidelines on HIV Testing Services https://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/(accessed: April2020).
7. Xu A. SL. · 2013 · 93
8. 10.1016/j.tibtech.2015.09.00110.1016/j.tibtech.2015.09.001 ↗
9. 10.1039/D0AN01098G10.1039/D0AN01098G ↗
10. 10.1002/anie.20141174110.1002/anie.201411741 ↗
11. 10.1038/s41579-020-00459-710.1038/s41579-020-00459-7 ↗
12. b)World Health Organization World Health Statistics 2020: Monitoring Health for the SDGs Sustainable Development Goals https://apps.who.int/iris/handle/10665/332070(accessed: April2020).
13. 10.1038/s41551-020-00654-010.1038/s41551-020-00654-0 ↗
14. 10.1038/s41551-020-00617-510.1038/s41551-020-00617-5 ↗
15. 10.1021/acsami.9b1788810.1021/acsami.9b17888 ↗
16. 10.1021/acsami.0c0789310.1021/acsami.0c07893 ↗
17. 10.1128/JCM.02487-0710.1128/JCM.02487-07 ↗
18. b)Lucira Health Inc. Lucira COVID‐19 All‐in‐One Test Kit Instructions for Use https://www.fda.gov/media/143808/download(accessed: July2021).
19. 10.1177/184954351770115810.1177/1849543517701158 ↗
20. 10.1038/s41565-021-00899-z10.1038/s41565-021-00899-z ↗
21. 10.1038/s41565-021-00907-210.1038/s41565-021-00907-2 ↗
22. 10.1016/j.cell.2016.09.01310.1016/j.cell.2016.09.013 ↗
23. 10.1002/anie.20140322210.1002/anie.201403222 ↗
24. 10.1039/C5SC04184H10.1039/C5SC04184H ↗
25. 10.1021/jacs.7b0705510.1021/jacs.7b07055 ↗
26. 10.1517/17425247.2011.55321710.1517/17425247.2011.553217 ↗
27. 10.1016/j.ejpb.2018.09.01610.1016/j.ejpb.2018.09.016 ↗
28. Bajaj S. · J. Appl. Pharm. Sci. · 2012 · 2 · 129
29. 10.1002/jps.2182510.1002/jps.21825 ↗
30. 10.1073/pnas.090033610610.1073/pnas.0900336106 ↗
31. 10.1021/mp500423z10.1021/mp500423z ↗
32. 10.1021/acs.langmuir.5b0375810.1021/acs.langmuir.5b03758 ↗
33. 10.1021/acs.biochem.8b0021710.1021/acs.biochem.8b00217 ↗
34. 10.1002/pro.310.1002/pro.3 ↗
35. 10.6064/2012/12617010.6064/2012/126170 ↗
36. 10.1117/1.JBO.20.5.05101510.1117/1.JBO.20.5.051015 ↗
37. 10.1039/C7RA11942A10.1039/C7RA11942A ↗
38. 10.1251/bpo5210.1251/bpo52 ↗
39. 10.1007/s10570-021-04083-310.1007/s10570-021-04083-3 ↗
40. 10.1007/BFb005098510.1007/BFb0050985 ↗
41. 10.1021/acssensors.9b0039010.1021/acssensors.9b00390 ↗
42. 10.1021/acs.analchem.0c0294010.1021/acs.analchem.0c02940 ↗
43. 10.1021/acsami.0c1636910.1021/acsami.0c16369 ↗
44. 10.1038/srep2100910.1038/srep21009 ↗
45. O'Farrel B. · 2013
46. 10.1161/CIR.000000000000061710.1161/CIR.0000000000000617 ↗
47. 10.1186/s11671-019-3240-310.1186/s11671-019-3240-3 ↗
48. 10.1038/s41586-020-2917-110.1038/s41586-020-2917-1 ↗
49. 10.1021/acsnano.7b0622910.1021/acsnano.7b06229 ↗
50. 10.1373/clinchem.2016.25510910.1373/clinchem.2016.255109 ↗
51. 10.1093/nar/28.12.e6310.1093/nar/28.12.e63 ↗
52. 10.1126/scitranslmed.abc707510.1126/scitranslmed.abc7075 ↗
53. 10.1073/pnas.201473911710.1073/pnas.2014739117 ↗
54. 10.1021/acssensors.9b0259510.1021/acssensors.9b02595 ↗
55. 10.2144/00011307210.2144/000113072 ↗
56. 10.7150/thno.1867510.7150/thno.18675 ↗
57. 10.1021/acssensors.9b0129910.1021/acssensors.9b01299 ↗
58. 10.1039/C9LC00506D10.1039/C9LC00506D ↗
59. 10.1038/s41598-019-51342-210.1038/s41598-019-51342-2 ↗
60. 10.1016/j.actatropica.2018.03.00410.1016/j.actatropica.2018.03.004 ↗
61. 10.1016/j.heliyon.2017.e0041510.1016/j.heliyon.2017.e00415 ↗
62. G. Lenk G. Stemme N. Roxhed 2014
63. A.Kols J.Sherris HPV Vaccines: Promise and Challenges https://screening.iarc.fr/doc/jsrp13710.pdf(accessed: April2020).